<SEC-DOCUMENT>0001193805-19-001361.txt : 20191022
<SEC-HEADER>0001193805-19-001361.hdr.sgml : 20191022
<ACCEPTANCE-DATETIME>20191022075833
ACCESSION NUMBER:		0001193805-19-001361
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191022
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191022
DATE AS OF CHANGE:		20191022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		191160582

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>e619134_8k-adma.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<U>October 22, 2019</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ADMA
    BIOLOGICS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; width: 34%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 33%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 33%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-36728</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56-2590442</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">465 State Route 17, Ramsey, New Jersey </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07446</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <U>(201) 478-5552</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last report.)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">o</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMA</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Global Market</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
                          8.01</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other
Events.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 22, 2019, ADMA Biologics, Inc. issued a press release
entitled &ldquo;ADMA Biologics Named Company of the Year by BioFlorida.&rdquo; The full text of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 9.01</B></TD><TD><B>Exhibits.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="e619134_ex99-1.htm" STYLE="-sec-extract: exhibit">Press release dated October 22, 2019, entitled &ldquo;ADMA Biologics Named Company of the Year by BioFlorida.&rdquo;</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SIGNATURE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 22, 2019</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADMA Biologics, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brian Lenz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Lenz</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>e619134_ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADMA Biologics Named Company of the Year
by BioFlorida</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RAMSEY, N.J. and BOCA RATON, FL., &ndash; October 22, 2019 &ndash;
ADMA Biologics, Inc. (NASDAQ: ADMA) (&ldquo;ADMA&rdquo; or the &ldquo;Company&rdquo;), a commercial biopharmaceutical company dedicated
to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at
risk for infection and the prevention of certain infectious diseases, today announced that it has been named Company of the Year
by BioFlorida, in recognition of ADMA&rsquo;s significant achievements over the past year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are honored to receive this award from BioFlorida
and to be recognized for the recent achievements at our Boca Raton, Florida biologics manufacturing and laboratory campus,&rdquo;
stated Adam Grossman, President and Chief Executive Officer. &ldquo;Over the past year, we were granted two U.S. Food and Drug
Administration (&ldquo;FDA&rdquo;) biologic product approvals for ASCENIV&trade; and BIVIGAM&reg;, improved our current good manufacturing
practice (&ldquo;cGMP&rdquo;) compliance classification with FDA, and secured funding that will support our ongoing commercial
product launches and operations. We are extremely proud of these accomplishments and attribute our success to our passionate and
dedicated team who worked so hard to revitalize our biologics manufacturing business. We look forward to continuing to contribute
to the growing pharma and biotech community in Florida and to continue to expand our operations and grow our workforce to support
the increasing demand of our therapeutic products.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;It is our pleasure to award ADMA as the BioFlorida Company
of the year based upon all of their recent regulatory, financial and growth achievements,&rdquo; stated Nancy Bryan, President
and Chief Executive Officer of BioFlorida. &ldquo;ADMA&rsquo;s growth is a testament to the business opportunities available in
Florida, where life science companies can achieve great things with our talent pool and resources.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About BioFlorida</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BioFlorida is the voice of Florida&rsquo;s life science industry,
representing 6,200 establishments and research organizations in the biopharmaceutical, medical technology, HealthIT and bioagriculture
sectors that collectively employ just over 87,000 Floridians. Members of the BioFlorida network include emerging and established
life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies,
investors and service providers. BioFlorida&rsquo;s member driven initiatives provide a strong business climate for the advancement
of innovative products and technology that improve lives and promote economic benefits to the state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ADMA Biologics, Inc. (ADMA)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ADMA Biologics is a commercial biopharmaceutical company dedicated
to manufacturing, marketing and developing specialty plasma-derived biologics for the treatments of immunodeficient patients at
risk for infection. ADMA currently manufactures and markets three United States Food and Drug Administration (&ldquo;FDA&rdquo;)
approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV&trade;
(immune globulin intravenous, human &ndash; slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM&reg;
(immune globulin intravenous, human) for the treatment of PI; and NABI-HB&reg; (hepatitis B immune globulin, human) to provide
enhanced immunity against hepatitis B. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune
globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management
of immune compromised patient populations who suffer from an underlying immune deficiency disease, or who may be immune compromised
for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to
certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note Regarding Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains &ldquo;forward-looking statements&rdquo;
pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (&ldquo;we&rdquo;,
&ldquo;our&rdquo; or the &ldquo;Company&rdquo;). Forward-looking statements include, without limitation, any statement that may
predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as &ldquo;estimate,&rdquo;
&ldquo;project,&rdquo; &ldquo;intend,&rdquo; &ldquo;forecast,&rdquo; &ldquo;target,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;planning,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&rdquo; &ldquo;is likely,&rdquo; &ldquo;will likely,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;may,&rdquo; or, in each case, their negative, or words or
expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about increasing
demand for our therapeutic products; our ability to continue contributing to the growing pharma and biotech community in Florida
and to continue to expand our operations and grow our workforce; and the potential of our specialty plasma-based biologics products
and product candidates to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease or
other indications. Actual events or results may differ materially from those described in this document due to a number of important
factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements
included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does
not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.
Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and
the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements,
including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission,
including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">COMPANY CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian Lenz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President and Chief Financial Officer | 201-478-5552
| www.admabiologics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTOR RELATIONS CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeremy Feffer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director, LifeSci Advisors, LLC | 212-915-2568 |</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !' .8# 2(  A$! Q$!_\0
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MU^WC\9[NYDE;XG^-PTC%B$U>9%!//"JP 'L!@5[O_P %V/\ D\;2/^Q5M?\
MTINZ^+J_N?POX5RB'#>%KO#0E.I'FE*44VV_-K9=%LC^'O$[BG-Y\1XJA]8F
MH4Y<L8QDTDE;HGN^KW9ZM_PW3\9?^BH>.O\ P=7'_P 51_PW3\9?^BH>.O\
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MPO&BK(< _(54\<%B<4?\$^_^"5G@/]K/]FVQ\9:_KGBZQU&ZO;FV:+3Y[=(
ML4A52 \+MDCKS7O2XRX(65?VQ&G!TN90=J2YE)IM)QM=:)Z[=CPH\&\:O-/[
M(E4FJO*YJ]5\KBFDVI7L]6M-SY>_X;I^,O\ T5#QU_X.KC_XJC_ANGXR_P#1
M4/'7_@ZN/_BJ_0;5?^""GPS?2[D67BSQW'>F)A;O-/:21I)@[2RB!2RYQD!@
M2.XZU^7/COP5J/PV\:ZMX?U>'[/JFBW<EE=1_P!R2-BK8]LCCVKT>%,\X2XB
ME4AEE&#=.UTZ<4[/JKK7;Y:=SSN*LCXLX>C3GF5::4[V:J2:NK:.ST_7Y'H'
M_#=/QE_Z*AXZ_P#!U<?_ !5'_#=/QE_Z*AXZ_P#!U<?_ !51_L:?LTW?[6G[
M0FB>#8))K:SN2USJ5W&,M9VD8S(XR"-Q^55R,;G7-?HE_P .%OA3_P!#1\0O
M_ NS_P#D:N;BCBC@[A_$QPF8T8*;7-:-).RO97LM+V.GACACB_/\-+%Y?6FX
M)\MW5DM='IKK:Z/SQ_X;I^,O_14/'7_@ZN/_ (JC_ANGXR_]%0\=?^#JX_\
MBJ]?_P""H/[ _A3]B*W\$MX8U3Q#J1\2M>K<_P!J2POY?D"WV[/+C3&?-;.<
M]!TKY*KZ/A^'#^<X"&98'#P=.=[7IQ3T;B]+=T?.9_+/\FQ\\NQN(FJD+7M4
MDUJE):W[-'JW_#=/QE_Z*AXZ_P#!U<?_ !5'_#=/QE_Z*AXZ_P#!U<?_ !5?
M4?[ _P#P2#T+]HWX 6GC3QOJ_B329=;F>33+;3)(8Q]E7Y5D?S(G)+L&(Q@;
M=IYSQZ7\5/\ @A#X*T_X;ZW<>$_$GC&?Q);V<DNFPWT]L]O/,HRL;A(%;#8V
MY!XSG!Q@_$XWC_@7"8^675J<.>,N5OV2Y4[V>MMD]V?;8+@'CG%8&.84:D^2
M4>9+VKYFK76E]VMD?"/_  W3\9?^BH>.O_!U<?\ Q5'_  W3\9?^BH>.O_!U
M<?\ Q5>67-M)97,D,J-'+"Y21&&"C X(/N#3*_3_ /5_*GJL-3_\ C_D?F3S
M_-4[/$U/_ Y?YGJW_#=/QE_Z*AXZ_P#!U<?_ !5'_#=/QE_Z*AXZ_P#!U<?_
M !5>4T4?ZO95_P! U/\ \ C_ )"_M_-/^@FI_P"!R_S/7-/_ &]_C1IE_#<1
M_$_QJTD$BR*)=5EEC)!R-R.2K#U# @]""*_3;_@E+^UC\1?VIOAKJMSXWTJ.
M:UTJ5+>T\01JD U%]HWQM$H WKPQ=0%^?& 1S^5?[-'[/.N?M0_&#2O"&@IB
MXOWW3W+1L\5C ,;YI-HX50?;)*C/(K]W?@K\)-*^!7PLT3PGHL,<6GZ):I;H
M5C"&9@/FD8#^)VRQ/4DGFOP#QUQ.18+!0RZCAJ?UF>J:BDX176ZM\6R3TW=M
M$?O?@;AL\QN-GF-;$5/JT-&G)M3DUM9W^%:MK797U9U-%4-/UDW6KWEG+$89
M+8JT9R2)XV'##CL<@CM@>HJ_7\GX;$TZ\'.D[I-KMK%M-:^:_I']43A*#M+^
MKA1116Y)^1G_  78_P"3QM(_[%6U_P#2F[KXNK[1_P""['_)XVD?]BK:_P#I
M3=U\7HC2N%4%F8X"@9)/H!7^@_AI_P DM@?^O:/X \2?^2HQW_7QGLG["'[*
MMY^UW^T+I?AU4(T6S(O];G)91%:(R[E##^-R0BC@\DY&"1^R?[4'QPTK]DG]
MG#7/$[0PQ0Z'9>1IMG&H1))R-EO"HX 7=MSCHH/'&*\M_P""5?[(4?[,/[.M
MIJ&I6;6_B_QC''J&J>:I62VC()AMRI^Z45LL, [V8'H,>R_'?]F[P7^TSX>L
M])\;Z.=<TVPN/M<%L;RXMT67:5#D1.FXA68#.<;CCJ:_F+Q(XVP6=<3TX8ER
ME@L/+EM&S<K/WVKM+WFK)W^%)^1_3/ASP7C,EX:G/#*,<9B(\UY72C=>XG9-
M^ZG=JWQ-KS//O^">/[8]K^V-\"+;4IY(4\5Z,$L]>MEVJ5FQQ.J _+'+M8KZ
M$./X<U\!?\%F/V1D^"/QOC\<Z/&PT'Q[++/<KQMM-0SNE P!\L@/F#DG=YG3
MC/Z3? ?]C'X:_LR:Y?:EX&\-#0;O4H!;7+I?W4ZS1A@P!661ER".#C(R>>33
MOVQ/V:[+]K+]G_6_!EU)#;7-XJSZ?=R)O%E=1G=')ZXSE6QR5=AWKS^&>-,N
MR3BUYAE:E#!U':49)749;Z)RTA+6.M[*QW\2\&9AG7"BR_-'&>,IJ\91;LY1
MVU:CK-:2Z7=S\KO^"-?_ "?SX:_Z\-0_])GK]/OV_?BSKWP,_9"\9^*_#-XM
MAKFD0V[VMPT*3",M<PQM\C@J?E=AR.]?FC_P27\+7_@?_@I#I>C:K;/9ZGI4
M.J6EU _6*5()%9>..H/(X/:OTT_;L^#>M?M _LG^+_!_AU;5]9UJ&!+9;F7R
MHB4N8I&RV#CY4;M7V'BU4PLN.L!4Q+BZ+C1<KV<>3VLKWZ.-M^ECY#PGIXJ/
M ^.IX92592K*-KJ2G[.-K=5*^W6Y^6/_  ^#_:"_Z'2T_P#!'8__ !JM;P'_
M ,%C?CK9>-=*DU'Q%IVL6 NXQ<64VDVL*7*%@&0O'&KKD'JIX..O2I_^')OQ
MR_Y]?"O_ (-__L*VOAW_ ,$0OB_=^-=.&LW/A?1],2=)+B[6]-RT:JP)VQJH
M+-QP,@9ZD=:_4L3BO#14976%V>T87^5E>_:VO8_,,-A?$KVT;/%;K>4[?.[M
M;O?3N?K7JVF0ZWI5S97*E[>[B:"50Q7<C J1D<C@GI7S)_P1_L(M*_8WBM8%
MVPVWB#5(HUSG:JW+ #/T%?3.M:M%H&C7=]/N\BRA>>3:,MM52QP.YP*^9?\
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M4@[NYS3/ G[(OP"^-?B%/#7@WXT:\WBO4T,>DPZMX>>VMKJX/"1,^,C)/;G
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M27X@^J_4\%6ERTF[^LYS5.'XRM_V]J?J/T<\GIU(XS,$KU%:*\HI.<OOT_\
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M>$X/AKXATW7+K3D\*6T+V<%M;R>>?-%N_P P)\B,[L<^:<GD5\K?\-A_%O\
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M]=\*\.X;(<HP^3X3X*,%%>=MV_.3NWYL_/L=C)XK$3Q%3>3N<E\8_@/X0_:
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$:"/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
